These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24909714)

  • 21. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
    Hakim GD; Akarsu M; Karademir S; Unek T; Astarcıoğlu İ
    Turk J Gastroenterol; 2014 Dec; 25(6):685-9. PubMed ID: 25599782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
    Dickson RC; Terrault NA; Ishitani M; Reddy KR; Sheiner P; Luketic V; Soldevila-Pico C; Fried M; Jensen D; Brown RS; Horwith G; Brundage R; Lok A
    Liver Transpl; 2006 Jan; 12(1):124-33. PubMed ID: 16382463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    McGonigal KH; Bajjoka IE; Abouljoud MS
    Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of patients with hepatitis B in special populations.
    Cholongitas E; Tziomalos K; Pipili C
    World J Gastroenterol; 2015 Feb; 21(6):1738-48. PubMed ID: 25684938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues.
    Patterson SJ; Angus PW
    Curr Opin Organ Transplant; 2009 Jun; 14(3):225-30. PubMed ID: 19373086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
    Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
    Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.
    Tanaka T; Renner EL; Selzner N; Therapondos G; Lilly LB
    Can J Gastroenterol Hepatol; 2014 Jan; 28(1):41-4. PubMed ID: 24212911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
    Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
    Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
    Teperman LW; Poordad F; Bzowej N; Martin P; Pungpapong S; Schiano T; Flaherty J; Dinh P; Rossi S; Subramanian GM; Spivey J
    Liver Transpl; 2013 Jun; 19(6):594-601. PubMed ID: 23447407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
    Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER
    Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
    Park J; Jung KS; Lee HW; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Gut Liver; 2017 Nov; 11(6):828-834. PubMed ID: 28651305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
    Kim LH; Chaung KT; Ha NB; Kin KC; Vu VD; Trinh HN; Nguyen HA; Nguyen MH
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):871-6. PubMed ID: 25919771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
    Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.